XtalPi

XtalPi Inc. is a biotechnology and technology company founded in 2015 on the MIT campus by three postdoctoral physicists. The company focuses on accelerating drug discovery and materials science research by integrating artificial intelligence, quantum physics, and robotics. XtalPi operates large-scale robotic labs in China and the United States and has received over $780 million in funding from global investors.

XtalPi offers AI-driven drug discovery services that utilize proprietary quantum algorithms to predict molecular structures and screen billions of molecules for promising drug candidates. The company also provides computational chemistry software platforms, such as XFEP and XMolGen, to enhance drug discovery efficiency. In addition to pharmaceuticals, XtalPi applies its expertise to material science, including partnerships for the commercialization of perovskite materials. Its division, Ailux Biologics, licenses biologics AI platforms like XtalFoldâ„¢ to partners, including Janssen Biotech. XtalPi serves nearly 80% of the top global pharmaceutical companies, reflecting its strong industry presence and trust in its technology.